Why Aurinia Pharmaceuticals stock crashed after hours on Friday

What happened

Actions of Pharmaceutical Aurinia (NASDAQ: AUPH) fell 18.1% in after-hours trading on Friday. The drugmaker’s inventory fell in response to a mixed bid of $ 250 million.

The accompanying prospectus filed with the Securities and Exchange Commission indicated that the proceeds from any sale of shares under this offering would be used for the clinical development and commercial production of the drug approved by the Food and Drug Administration for the Lupus nephritis (LN) Lupkynis. It would advance its pipeline, business development opportunities, capital spending and working capital.

By the end of the third quarter, Aurinia had a cash flow trail of around six to maybe eight quarters, depending on Lupkynis’ business trajectory, as well as the company’s clinical development plans.

Image source: Getty Images.

So what

Shareholders are hitting the exits on this biotech stock for a clear reason: This mixed plateau bid may spell the end of buyout talks. Aurinia shares soared last month following rumors that Bristol Myers Squibb (NYSE: BMY) was considering an offer for the company. Soon after, more rumors surfaced claiming that Aurinia had multiple suitors. To date, however, no formal takeover bid has yet been completed by either party.

And while neither Bristol nor Aurinia have publicly denied these rumors, there are obvious issues with this hypothetical tie-up. Specifically, Bristol has several holes to fill to keep its revenue in the right direction, and only around $ 16 billion in cash to meet that target. Aurinia, for her part, is unlikely to accept an offer of less than $ 6 billion. In addition, biotech could expect an offer of more than $ 8 billion.

Now what

Is Aurinia’s stock a screaming buy after this after-hours drop? The answer is most definitely yes. While sales of Lupkynis may be slow to increase with Aurinia at the helm, the drug is starting to turn heads among prescribers, according to a recent survey. As such, Aurinia’s top line is expected to grow in leaps and bounds eventually. Savvy investors should therefore not hesitate to take advantage of this unjustified decline in this undervalued biotech value.

10 stocks we prefer at Aurinia Pharmaceuticals
When our award-winning team of analysts have stock advice, it can pay off to listen. After all, the newsletter they’ve been running for over a decade, Motley Fool Equity Advisor, has tripled the market. *

They just revealed what they think are the top ten stocks investors can buy right now … and Aurinia Pharmaceuticals was not one of them! That’s right – they think these 10 stocks are even better buys.

See the 10 actions

* The portfolio advisor returns on November 10, 2021

Georges budwell has no position in any of the stocks mentioned. The Motley Fool owns stock and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Source link

Comments are closed.